2017
Sipuleucel-T (sip-T) to induce cytolytic T lymphocyte (CTL) activity against target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC).
Drake C, Antonarakis E, Petrylak D, Quinn D, Kibel A, Chang N, Dearstyne E, Campogan D, Haynes H, Vu T, Sheikh N, Small E. Sipuleucel-T (sip-T) to induce cytolytic T lymphocyte (CTL) activity against target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC). Journal Of Clinical Oncology 2017, 35: 5046-5046. DOI: 10.1200/jco.2017.35.15_suppl.5046.Peer-Reviewed Original ResearchCastration-resistant prostate cancerPeripheral blood mononuclear cellsCTL lytic activityCD107a expressionOverall survivalT cellsImmune responseSymptomatic metastatic castration-resistant prostate cancerMetastatic castration-resistant prostate cancerCytolytic T lymphocyte activityAntigen-specific cellular responsesAutologous cellular immunotherapyGreater CTL activityHealthy donor controlsRobust CTL responsesT lymphocyte activityCD8 T cellsLonger overall survivalAntigen-specific proliferationBlood mononuclear cellsHumoral immune responseLytic activityOS benefitMCRPC patientsMetastatic CRPCSipuleucel-T (sip-T) induced lytic CD8+ T cell responses to target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC).
Antonarakis E, Quinn D, Kibel A, Petrylak D, Vu T, Campogan D, Chang N, Trager J, Sheikh N, Drake C. Sipuleucel-T (sip-T) induced lytic CD8+ T cell responses to target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC). Journal Of Clinical Oncology 2017, 35: 162-162. DOI: 10.1200/jco.2017.35.7_suppl.162.Peer-Reviewed Original ResearchCastration-resistant prostate cancerT cell responsesCarboxyfluorescein succinimidyl esterProstatic acid phosphataseCTL activityCell responsesLytic abilityT cellsImmune responseProliferative responseSymptomatic metastatic castration-resistant prostate cancerAutologous peripheral blood mononuclear cellsMetastatic castration-resistant prostate cancerAntigen-specific CTL activityPeripheral blood mononuclear cellsSubset of ptsAntigen-specific CD8Vitro antigen stimulationBlood mononuclear cellsGranulocyte-macrophage colony-stimulating factorTumor cell lysisIntracellular granzyme BMononuclear blood cellsMacrophage colony-stimulating factorColony-stimulating factorCytokine profile of sipuleucel-T (sip-T) in differentiating reactivation of latent immunity from de novo immune responses.
Drake C, Petrylak D, Antonarakis E, Kibel A, Chang N, Vu T, Campogan D, Haynes H, Trager J, Sheikh N, Quinn D. Cytokine profile of sipuleucel-T (sip-T) in differentiating reactivation of latent immunity from de novo immune responses. Journal Of Clinical Oncology 2017, 35: 163-163. DOI: 10.1200/jco.2017.35.7_suppl.163.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerPeripheral blood mononuclear cellsProstatic acid phosphataseT cell responsesT cellsIL-2Cytokine profileImmune responseSymptomatic metastatic castration-resistant prostate cancerAutologous peripheral blood mononuclear cellsWk 6Cell responsesDe novo immune responsesCastration-resistant prostate cancerNovo immune responsesIntracellular IL-2IFN-γ levelsMemory T cellsBlood mononuclear cellsPre-existing immunityT cell proliferationGranulocyte-macrophage colony-stimulating factorCytokine release profileMacrophage colony-stimulating factorColony-stimulating factorAntigen spread (AgS) after sipuleucel-T (sip-T): A cross-trial comparison of 4 sip-T clinical trials of patients (pts) with prostate cancer (PC).
Fong L, Small E, Petrylak D, Quinn D, Antonarakis E, Kibel A, Chang N, Kandadi H, Sheikh N, Drake C. Antigen spread (AgS) after sipuleucel-T (sip-T): A cross-trial comparison of 4 sip-T clinical trials of patients (pts) with prostate cancer (PC). Journal Of Clinical Oncology 2017, 35: 143-143. DOI: 10.1200/jco.2017.35.6_suppl.143.Peer-Reviewed Original ResearchMetastatic castration-resistant PCProstatic acid phosphataseProstate cancerIgG responsesDisease courseSymptomatic metastatic castration-resistant prostate cancerMetastatic castration-resistant prostate cancerAntigen-presenting cell activationCastration-resistant prostate cancerPeripheral blood mononuclear cellsAndrogen-dependent prostate cancerBlood mononuclear cellsCross-trial comparisonsCancer-related antigensGranulocyte-macrophage colony-stimulating factorMacrophage colony-stimulating factorColony-stimulating factorImproved OSAndrogen suppressionClinical benefitAutologous immunotherapyDisease stageMononuclear cellsAntibody responseClinical trials
2016
Sipuleucel-T (sip-T)–induced proliferative CD8+ T-cell responses to immunizing and secondary antigens.
Antonarakis E, Quinn D, Kibel A, Petrylak D, Chang N, Cummings C, Chinn J, Pufnock J, Sheikh N, Drake C. Sipuleucel-T (sip-T)–induced proliferative CD8+ T-cell responses to immunizing and secondary antigens. Journal Of Clinical Oncology 2016, 34: 165-165. DOI: 10.1200/jco.2016.34.2_suppl.165.Peer-Reviewed Original ResearchT cell responsesMetastatic castration-resistant prostate cancerProstatic acid phosphataseGranulocyte macrophage-colony stimulating factorSecondary antigensProliferative CD8Immune responseSymptomatic metastatic castration-resistant prostate cancerCell responsesCastration-resistant prostate cancerPeripheral blood mononuclear cellsAntigen-specific CD8Improved overall survivalT-cell involvementCellular immune responsesT cell subpopulationsBlood mononuclear cellsTumor cell lysisMacrophage-colony stimulating factorAntigen spreadEvaluable ptsOverall survivalWeek 26Autologous immunotherapyMononuclear cellsChanges in T cell immunity in patients with metastatic castration resistant prostate treated with Radium-223 treatment.
Kim J, Kang Y, Shin M, Deshpande H, Hurwitz M, Roberts J, Cardinale J, Narayana A, Kang I, Petrylak D. Changes in T cell immunity in patients with metastatic castration resistant prostate treated with Radium-223 treatment. Journal Of Clinical Oncology 2016, 34: 295-295. DOI: 10.1200/jco.2016.34.2_suppl.295.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerPeripheral blood mononuclear cellsT cell immunityT cellsCell immunityOsseous metastasesMetastatic castration-resistant prostateCastration-resistant prostate cancerIL-7 receptor alpha chainRadium-223 treatmentEffector memory CD8PD-1 expressionEffector T cellsDeath protein 1Resistant prostate cancerCastration-resistant prostateBlood mononuclear cellsFollowing time pointsCocktail of antibodiesHost immune systemReceptor alpha chainCalcium mimeticEligible patientsEM CD8Median PSA